Anti-TSG101 antibodies and their uses for treatment of viral infections
AssigneeFunctional Genetics, Inc.
InventorLimin Li
Life of this patent
Estimating the term…
Abstract
The present invention provides methods of using antibodies that bind a TSG101 protein to inhibit or reduce viral production. The invention also provides methods of using the TSG101 antibodies for the treatment of viral infections, including HIV infection. The invention further provides methods of detecting viral infected cells using TSG101 antibodies.
Claims11
A method for ex vivo removal of cells infected by an enveloped virus selected from the group consisting of human immunodeficiency virus type I (HIV-1), human immunodeficiency virus type II (HIV-II), Marburg virus, Ebola virus, and simian immunodeficiency virus, from a fluid obtained from a mammal, comprising:
- (a) incubating said fluid with a sufficient amount of a TSG 101 antibody that binds TSG101 protein found on a membrane surface of said cells;
- and
- (b) removing cells bound by said TSG 101 antibody from said fluid;
- wherein said antibody binds the N-terminal or C-terminal region of said TSG 101 protein.
Dependencies are inferred from the claim text.